Donnellan E,Khorana AA .2017 .Cancer and venous thromboembolic disease: A review. Oncologist, 0214(2) : 199-207.
Mulder FI,Horvath-Puho E,van Es N,Laarhoven HWM,Pedersen L,Moik F .2020 .Venous thromboembolism in cancer patients: A population-based cohort study. Blood, 10(14) : 1959-69.
Lanting VR,Takada T,Bosch FT,Marshall A,Grosso MA,Young AM .2018 .Risk of recurrent venous thrombo-embolism in patients with cancer: An individual patient data metaanalysis and development of a prediction model. Thromb Haemost, 78(6) : 589-96.
Bertoletti L,Girard P,Elias A,Espitia O,Schmidt J,Couturaud F .2023 .Recurrent venous thromboembolism in anticoagulated cancer patients: Diagnosis and treatment. Arch Cardiovasc Dis, 11(1) : 84-93.
McBane II RD,Vlazny DT,Houghton D,Casanegra AI,Froehling D,Daniels P .2023 .Survival implications of thrombus recurrence or bleeding in cancer patients receiving anticoagulation for venous thromboembolism treatment. Thromb Haemost, 10(5) : 535-44.
Araji G,Wei C,Chowdhry V,Wu K,Khamis Z,Sarkis T .2024 .Cancer-associated venous thromboembolism among solid and haematological malignancies: A comprehensive national study. Blood, 10(1) : 2641.
Sheth RA,Niekamp A,Quencer KB,Shamoun F,Knuttinen MG,Naidu S .2017 .7(Suppl 3): S178. Cardiovasc Diagn Ther, 11 : .
Ay C,Pabinger I,Cohen AT .2017 .Cancer-associated venous thromboembolism: Burden, mechanisms, and manage-ment. Thromb Haemost, 10(2) : 219-30.
Uno H,Xiong H,Cronin C,Schrag D,Connors JM .2024 .Predictors of recurrent venous thromboembolism and major bleeding in patients with cancer: A secondary analysis of the CANVAS trial. Thromb Res, 109184 : 109184.
Moik F,Englisch C,Pabinger I,Ay C .2021 .Risk assessment models of cancer-associated thrombosis potentials and perspectives. Thromb Update, 100075 : 100075.
Yhim HY .2022 .Challenging issues in the management of cancerassociated venous thromboembolism. Blood Res, 2022025(S1) : 44-8.
Key NS,Khorana AA,Kuderer NM,Bohlke K,Lee AY,Arcelus JI .2023 .Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline updateJ. Clin Oncol, 10(16) : 3063-71.
Pritchard ER,Murillo JR,Putney D,Hobaugh EC .2019 .Singlecenter, retrospective evaluation of safety and e cacy of direct oral anticoagulantsversus low-molecular-weight heparin and vitamin K antagonist in patients with cancer. J Oncol Pharm Pract, 10(1) : 52-9.
Xiang E,Ahuja T,Raco V,Cirrone F,Green D,Papadopoulos J .2018 .Anticoagulation prescribing patterns in patients with cancer. J Thromb Thrombolysis, 10(1) : 89-98.
Fovel LM,Seabury RW,Miller CD,Darko W,Probst LA,Horvath L .2021 .Safety and e cacy of direct oral anticoagulant therapy in patients with cancer. J Pharm Pract, 10(5) : 710-4.
Alsubaie NS,Al Rammah SM,Alshouimi RA,Alzahrani MY,Al Yami MS,Almutairi AR .2021 .The use of direct oral anticoagulants for thromboprophylaxis or treatment of cancer-associated venous thromboembolism: A meta-analysis and review of the guidelines. Thromb J, 10(1) : 76.
Zhou H,Ye LL,Zhou JT,Ma FX,Ma JJ,Zhang JH .2024 .Direct oral anticoagulants (DOACs) versus low-molecular-weight heparin (LMWH) for extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: A systematic review and meta-analysis. Surg Endosc, 10(3) : 1131-8.
Adrian SG,Perez CI,Carmona-Bayonas A,Moran LO,Perez JR,Del Prado PM .2024 .Cancer-related thrombosis: Impact of biological sex on the risk of rethrombosis and bleeding. Haematologica, 286152 : .
Joyce E,Haymart B,Kong X,Ali MA,Carrigan M,Kaatz S .2022 .Length of anticoagulation in provoked venous thromboembolism: A multicenter study of how real-world practice mirrors guideline recommendations. J Am Heart Assoc, 10(21) : .
Alexander P,Visagan S,Issa R,Gorantla VR,Thomas SE .2021 .Current trends in the duration of anticoagulant therapy for venous thromboembolism: A systematic review. Cureus, 10(10) : .